In Context
∙ The apex drug regulatory body Central Drugs Standard Control Organisation (CDSCO), has approved use of Jardiance for treating kidney failure.
About
∙ The drug Jardiance (empagliflozin) 10mg tablets has been approved to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR) which is done to check how well the kidneys are filtering.
∙ Earlier, the Jardiance was given approval only for the treatment of heart failure with reduced ejection fraction (HFrEF).
∙ Significance: The approval has the potential to advance the standard of care for an estimated more than 33 million adults in India living with chronic kidney disease (CKD).
∙ It can help relieve the burden on healthcare systems by reducing the risk of hospitalizations.
∙ It will also delay the progression to kidney failure, for people with CKD.
